

# MIGRAINE IS MORE THAN JUST A HEADACHE

It is a long-term and often disabling neurological disease<sup>1-3</sup>

## Migraine is a global problem...


- ▶ Affects > 10% of population (~ 1 billion globally)<sup>3,4</sup>
- ▶ One of the leading causes of years lived with disability<sup>3</sup>
- ▶ Peaks during prime productive years (30–49 years of age)<sup>1</sup>
- ▶ 2–3 times more prevalent in women than in men<sup>1</sup>

## ...that disrupts several domains of patients' lives<sup>1,2</sup>



### Personal and Family

Migraine may **disrupt** patients' everyday functioning:<sup>1,2</sup>



### Comorbidities

Patients with migraine often have other conditions:<sup>5,\*</sup>



Respiratory



Cardiovascular



Psychiatric

+




Other pain

The presence of comorbid conditions can affect treatment decisions<sup>6</sup>

### Severity

~ **54%** report severe impairment or the need for bed rest<sup>1</sup>



~ **28%** of people with migraine have  $\geq 4$  headache days/month<sup>7</sup>

### Economics

**0.5–1** day of work lost per week<sup>8</sup>



Healthcare costs increase with disease severity<sup>9</sup>



## Why measure functional disability?



Expands the physician's understanding of the patient's experience<sup>2</sup>

Increases likelihood of physicians recommending appropriate management and follow-up<sup>10</sup>

## How can functional disability be assessed?

Ask open-ended questions<sup>2</sup>

Use validated migraine-specific patient-reported outcome tools, such as:<sup>11,12</sup>

MIDAS • HIT-6 • MSQ • MFIQ



This infographic is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease.

\*Note that this is not an exhaustive list of possible comorbidities.

HIT-6, Headache Impact Test; MFIQ, Migraine Functional Impact Questionnaire; MIDAS, Migraine Disability Assessment; MSQ, Migraine-Specific Quality of Life Questionnaire.

1. Lipton RB, et al. *Neurology*. 2007;68:343-349. 2. Buse DC, et al. *Mayo Clin Proc*. 2009;84:422-435. 3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. *Lancet*. 2018;392:1789-1858. 4. Stovner LJ, et al. *Cephalalgia*. 2007;27:193-210. 5. Lipton RB, et al. *Headache*. 2018;58:933-947. 6. Silberstein SD, et al. *Neurology*. 2012;78:1337-1345. 7. Houle TT, et al. *Headache*. 2013;53:908-919. 8. Serrano D, et al. *Value Health*. 2013;16:31-38. 9. Silberstein SD, et al. *Headache*. 2018;58:1579-1592. 10. Holmes WF, et al. *Headache*. 2001;41:343-350. 11. Buse DC, et al. *Curr Pain Headache Rep*. 2012;16:237-254. 12. Hareendran A, et al. *Headache*. 2018;58:1612-1628.